Severe Hypertriglyceridemia (sHTG) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

Severe Hypertriglyceridemia (sHTG) Market Outlook

Thelansis’s “Severe Hypertriglyceridemia (sHTG) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Severe Hypertriglyceridemia (sHTG) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Severe Hypertriglyceridemia (sHTG) Overview

Hypertriglyceridemia is a prevalent metabolic disorder characterized by elevated levels of triglycerides, a type of fat, in the bloodstream. It is a triglyceride concentration greater than 150 mg/dL in the blood. This condition has been linked to various diseases, including atherosclerosis, obesity, and insulin resistance, increasing the risk of cardiovascular disease (CVD). Severe hypertriglyceridemia (sHTG), defined as fasting triglyceride concentrations above 10.0 mmol/L, can be classified into two categories: 1. Polygenic hypertriglyceridemia (also known as type V hyperlipoproteinemia according to the Fredrickson classification) is caused by a combination of genetic, demographic, and clinical factors, including obesity, diabetes mellitus, untreated hypothyroidism, alcohol consumption, and certain medications. 2. Familial chylomicronemia syndrome (also known as type I hyperlipoproteinemia, according to the Fredrickson classification) is a genetic disorder. Both forms are associated with elevated fasting chylomicronemia and very low-density lipoprotein levels. Familial chylomicronemia syndrome tends to be more severe and resistant to treatment. The clinical symptoms of severe hypertriglyceridemia with chylomicrons include abdominal pain and acute pancreatitis. The biochemical thresholds for hypertriglyceridemia are: normal (<1.7 mmol/L), borderline high (1.7 to 2.3 mmol/L), high (2.3 to 5.6 mmol/L), and very high (>5.6 mmol/L). A triglyceride level greater than 10.0 mmol/L is considered severely elevated and increases the risk of pancreatitis. Severe hypertriglyceridemia is usually diagnosed through a routine blood test known as a lipid profile. The risk factors for severe hypertriglyceridemia include genetic disorders, obesity, untreated diabetes, and certain medications. Individuals with extremely high levels of triglycerides may experience symptoms such as abdominal pain, nausea, vomiting, yellow-colored skin bumps (xanthomas), and acute pancreatitis.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources &amp; assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Severe Hypertriglyceridemia (sHTG) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034